INSIGHTS ON CELL & GENE THERAPY LOGISTICS
-
Do ClinOps Professionals Understand The CAR-T Supply Chain?
Lee Clough RN, HP, of Novartis talks about the importance of understanding the nuances associated with collecting and shipping autologous material (i.e., CAR-Ts) for clinical trials.
-
A Comparative Guide To CGTs: Modalities, Landscape, And Logistics
Cell and gene therapies (CGTs) have the potential to revolutionize medicine. However, achieving therapeutic success requires advanced logistical consideration to ensure product safety and efficacy
-
End-To-End Cold Chain Management: A Next-Generation Approach
Three experts in cold chain management walk through the advantages of end-to-end platforms for bulk drug substance management.
-
Cryopreservation Best Practices For Cell & Gene Therapy Source Material
Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.
-
Formula For Pharmaceutical Logistics And Supply Chain Success In 2024
Join global logistics leaders for an in-depth analysis of the evolving pharmaceutical supply chain, exploring critical issues, emerging trends, and strategies for navigating the complexities of 2024.
-
New DSCSA Guidance Details Layers Of Verification System Requirements
A recent FDA final guidance interpreting the DSCSA details verification systems expectations for trading partners. Just how they should meet these expectations, however, remains unclear.
-
A Step-By-Step Guide To Cell Banking
Cell banking stands at the forefront of medical advancement. This guide delves into the steps involved in protecting these priceless resources, from cell collection and processing to storage and cell expansion.
-
Exploring The Landscape, Modalities, And Logistics Of CGTs
Explore the latest market trends and the nuances of various cell and gene therapy modalities, along with the logistical considerations necessary to safeguard product quality and safety.
-
The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility
Deciding whether to bring manufacturing in-house or outsource it to a partner can be a daunting decision, particularly as market forces continue to put pressure on small biotechs.
-
mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A
During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, our expert panelists answered audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.